FAK (Ab 861) Antilichaam

Non-receptor protein-tyrosine kinase implicated in signaling pathways involved in cell motility, proliferation and apoptosis. Activated by tyrosine-phosphorylation in response to either integrin clustering induced by cell adhesion or antibody cross-linking, or via G-protein coupled receptor (GPCR) occupancy by ligands such as bombesin or lysophosphatidic acid, or via LDL receptor occupancy. Plays a potential role in oncogenic transformations resulting in increased kinase activity.

5747

Q05397

NP_005598.3

Human, Mouse, Rat

FAK (Ab-861) antibody was raised against a peptide sequence around aa. 859~863 (H-I-Y-Q-P) derived from Human FAK.

Unconjugated

Primary Antibodies

Other

Antibodies were purified by affinity-chromatography using epitope-specific peptide.

1 mg/mL

Antibody supplied in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.

None

Blue Ice

Store antibody at -20˚ C for up to one year.

125 kDa

This antibody detects endogenous level of total FAK protein.

Western Blot: 1:500~1:1000, Immunohistochemistry: 1:50~1:100

PTK2

Protein tyrosine kinase 2

Homo sapiens

Shi Q, et al. (2003) Mol Biol Cell; 14 (10) : 4306-15. Vadlamudi RK, et al. (2003) FEBS Lett; 543 (1-3) : 76-80. Eliceiri BP, et al. (2002) J Cell Biol Apr 01; 157 (1) : 149-60. Abu-Ghazaleh R, (2001) et al. Biochem J; 360 (Pt 1) : 255-64. Slack JK, et al. (2001) Oncogene; 20 (10) : 1152-63.

FAK, FADK, FAK1, FRNK, PPP1R71, p125FAK, pp125FAK, KIAA0288, FADK 1, PTK2

WB, IHC

27886593

Liquid